[Anti-viral therapy of type B chronic hepatitis. 3. Future of anti-viral agents].
Kato
Naoya
N
Goto
Tadashi
T
Omata
Masao
M
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D000068679:Emtricitabine; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D019384:Nucleic Acid Synthesis Inhibitors; D009705:Nucleosides / Q000627:therapeutic use; D063065:Organophosphonates / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D000077712:Telbivudine; D000068698:Tenofovir; D013936:Thymidine / Q000031:analogs & derivatives
D000998:Antiviral Agents; D019384:Nucleic Acid Synthesis Inhibitors; D009705:Nucleosides; D063065:Organophosphonates; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D003841:Deoxycytidine; D000077712:Telbivudine; D007372:Interferons; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine; D013936:Thymidine